Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28166558 | 0.97 | ALDH1A1 (0.59) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL2587720 | 0.86 | ALDH1A1 (0.44) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL564467 | 0.83 | ALDH1A1 (0.64) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL29255431 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL619004 | 0.82 | LMNA (0.41) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL9528672 | 0.81 | ALDH1A1 (0.52) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL28051 | 0.81 | PSIP1 (0.47) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL17997014 | 0.79 | ALDH1A1 (0.64) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL28932041 | 0.79 | ALDH1A1 (0.38) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A | |
| SCHEMBL28865930 | 0.79 | ALDH1A1 (0.38) | ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3053944-B1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | SHINETSU CHEMICAL CO (JP) | 2021-10-06 | — | — | EP | claimed |
| WO-2016205798-A1 | SELECTIVE ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2016154120-A1 | POLYPEPTIDES, PEPTIDES, AND PROTEINS FUNCTIONALIZED BY ALKYLATION OF THIOETHER GROUPS VIA RING-OPENING REACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-29 | — | — | WO | claimed |
| CN-101679411-B | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL | 2013-04-17 | — | — | CN | claimed |
| EP-2098508-B1 | Processes for preparing cyclic derivatives which are modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2012-06-20 | — | — | EP | claimed |
| WO-2012000608-A2 | NOVEL BETA-AMINOALDEHYDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR CHEMICAL USE AS REACTIVE INTERMEDIATES | GLUESENKAMP KARL-HEINZ (DE) | 2012-01-05 | — | — | WO | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| EP-1011665-A4 | HETEROCYCLIC AGENTS | LILLY CO ELI (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1011665-A1 | HETEROCYCLIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | claimed |
| WO-1998040068-A1 | HETEROCYCLIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-09-17 | — | — | WO | claimed |
| US-5530124-A | Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-25 | — | — | US | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| US-4778790-A | HYPOTENSIVE AGENTS | SANKYO COMPANY LIMITED (JP) | 1988-10-18 | — | — | US | claimed |
| US-4650868-A | 7-deazapurine derivatives useful as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-17 | — | — | US | claimed |
| EP-0002680-A2 | 4-Spectinomycylamin and its physiologically acceptable salts, method of preparation and pharmaceutical products containing these substances | Dr. Karl Thomae GmbH (DE) | 1979-07-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | ALDH1A1 311/4885CYP2C19 292/4885CYP3A4 656/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | ALDH1A1 790/4885CYP2C19 262/4885CYP3A4 457/4885 |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | PSEN2, PSEN1, CHAT | ALDH1A1 543/4885CYP2C19 1204/4885CYP3A4 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.